Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA MUTATION
PIK3CA MUTATION - Associated Disease
- head and neck cancer
- Source Database
- CIViC Evidence
- Description
- 6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1364
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/311
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Head And Neck Cancer
- Evidence Direction
- Does Not Support
- Drug
- Pictilisib,Trametinib,Tanespimycin
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25855885
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Pictilisib | Sensitivity | false |
| Tanespimycin | Sensitivity | false |
| Trametinib | Sensitivity | false |